The entire clinical development process may last 6-11 years. WuXi’s phase 1 and phase ... can’t manufacture everything in-house. Biologics manufacturing requires quality certificates and ...

Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

Launching the Water Excellence Stewardship (WES) program to advance UN Sustainable Development Goal 6 (SDG6 ... 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract ...

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received 2025 CDMO Leadership Awards in the ...

2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been recognized by the environmental non-profit ...

As a contributor to the United Nations Sustainable Development Goal 6 (SDG6), WuXi ... WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing ...